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We evaluated the pre-clinical efficacy of a novel intraperitoneal (i.p.) sustained-release paclitaxel formulation (PTXePC) using
bioluminescent imaging (BLI) in the treatment of ovarian cancer. Human ovarian carcinoma cells stably expressing the firefly luciferase
gene (SKOV3
Luc) were injected i.p. into SCID mice. Tumour growth was evaluated during sustained or intermittent courses of i.p.
treatment with paclitaxel (PTX). In vitro bioluminescence strongly correlated with cell survival and cytotoxicity. Bioluminescent
imaging detected tumours before their macroscopic appearance and strongly correlated with tumour weight and survival. As
compared with intermittent therapy with Taxol
s, sustained PTXePC therapy resulted in significant reduction of tumour proliferation,
weight and BLI signal intensity, enhanced apoptosis and increased survival times. Our results demonstrate that BLI is a useful tool in
the pre-clinical evaluation of therapeutic interventions for ovarian cancer. Moreover, these results provide evidence of enhanced
therapeutic efficacy with the sustained PTXePC implant system, which could potentially translate into successful clinical outcomes.
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Ovarian cancer accounts for the majority of deaths from
gynaecological malignancies and remains the fifth most common
cancer among women (Ozols, 2003). Ovarian cancer is generally
clinically silent, and therefore at the time of diagnosis the majority
of patients present with advanced peritoneal metastatic disease
(Bookman and Ozols, 1996; Trimble, 2006). Although a high
proportion of patients attain complete clinical remission following
initial treatment, unfortunately most relapse. The lack of early
detection, metastasis and resistance to chemotherapy make it one
of the most difficult malignancies to diagnose and treat, leaving
patients with very poor prognosis.
As ovarian cancer is predominantly confined to the peritoneal
cavity, strategies such as localised and sustained chemotherapy
may have the potential to improve the outcome of chemotherapy.
Indeed, several clinical trials have demonstrated survival advan-
tages with localised intraperitoneal (i.p.) chemotherapy and the
National Cancer Institute recommends surgery followed by
combination of intravenous and i.p. chemotherapy (Ozols et al,
1999; Polyzos et al, 1999; Markman, 2001; Ozols, 2003; Rothenberg
et al, 2003; Armstrong et al, 2006; Walker et al, 2006).
Unfortunately, the majority of patients fail to complete i.p. therapy
because of catheter-related complications. Therefore more toler-
able therapeutic interventions are required and in this context, we
developed a novel implantable paclitaxel drug delivery system
(PTXePC). Our initial studies demonstrated that PTXePC provided
local and controlled release of PTX over several weeks and that it
was safer and better tolerated than commercially available PTX
formulated in Cremophor EL (Grant et al, 2005; Ho et al, 2005;
Vassileva et al, 2007).
The availability of an intraperitoneal drug delivery system could
therefore allow for further exploitation of the benefits of
intraperitoneal chemotherapy while also solving the difficulties
associated with the catheter system. We therefore, utilised our
formulation and bioluminescent imaging (BLI) to determine
whether there are therapeutic advantages in providing sustained
vs intermittent intraperitoneal chemotherapy in ovarian cancer.
Establishment of a reliable ovarian cancer xenograft model is an
important step in the pre-clinical evaluation of potential treat-
ments. However, monitoring the development and progression of
peritoneal disease is difficult. Traditional assessments of efficacy
are based on measuring total tumour mass, including areas of
necrosis and oedema and do not necessarily evaluate the effects of
treatment on the number of viable tumour cells without additional
processing and evaluation. In this context, animals must be killed
at pre-determined end points, increasing the number of animals
required and limiting the possibility of ongoing observation of
tumour progression within the same animal. Recently BLI has
emerged as a real-time non-invasive method to follow tumour
progression (Contag et al, 1997; Edinger et al, 2003; Jenkins et al,
2003a,b; Hollingshead et al, 2004; Craft et al, 2005). Biolumines-
cent imaging detects only live, metabolically active tumour cells,
which is important in the monitoring of a therapeutic response
(Jenkins et al, 2003a,b; Hollingshead et al, 2004; Sato et al, 2004).
Although in recent years BLI has been widely utilised, to date there
are scarce reports on BLI and ovarian cancer and none in
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sparticular on sustained intraperitoneal chemotherapy. We there-
fore, stably transfected the SKOV3 human ovarian carcinoma cell
line with the firefly luciferase gene and utilised BLI to evaluate the
effects of sustained and intermittent i.p. Paclitaxel chemotherapy
on ovarian tumour response.
MATERIALS AND METHODS
Tumour cell line co-transfection and selection
The SKOV3 human ovarian adenocarcinoma cell line was obtained
from the American Type Culture Collection (Rockville, MD, USA).
Cells were grown in monolayer cultures in RPMI-1640 medium
supplemented with 10% fetal bovine serum and 1% penicillin/
streptomycin (Invitrogen, Burlington, ON, Canada) in a humidi-
fied atmosphere of 5% CO2. SKOV3 cells were stably co-transfected
with the modified firefly luciferase gene plasmid, pGL3 enhancer
vector and the pCI-neo mammalian expression vector for
neomycin selection (Promega, Madison, WI, USA) with the
Fugene-6 transfection kit (Roche, Laval, QC, Canada). Following
transfection, cells were cultured in G418 sulfate (800mgml
 1)
containing medium for 10 days. Surviving colonies were exposed
to 1mMD -luciferin potassium salt (Promega, Madison, WI, USA)
and imaged by IVISt Imaging System (Xenogen, Alameda, CA,
USA) for selection of stably co-transfected luciferase/neo clones
(SKOV3
Luc). Following isolation, SKOV3
Luc cells were maintained
and propagated in 400mgml
 1 G418 sulfate-containing medium.
SKOV3
Luc cells were imaged each week to ensure sustained
luciferase expression and studies were commenced 2 months post
transfection. Furthermore, to evaluate the stable expression of
luciferase over time, SKOV3
Luc cells were continuously cultured in
G418 sulfate-free media for 3 months and were periodically
imaged. Luciferase expression remained stable relative to the initial
imaging results.
PTX cytotoxicity in SKOV3
Luc cells
Exponentially growing SKOV3
Luc cells were exposed to various
PTX concentrations ranging from 0 to 17080nM for 24, 48
and 72h. Cells were then exposed to D-luciferin potassium
salt, 1mM in phosphate-buffered saline (Promega, Madison, WI,
USA) and imaged to determine bioluminescence as described
below. Cell viability was determined by the MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-di.p.henyl tetrazolium bromide] assay
as described earlier (Mosmann, 1983; Ho et al, 2005) and the %
cell survival was determined as: ((absorbance(l¼560nm) treated C
absorbance (l¼560nm) untreated) 100). Linear regression analysis
was performed to determine whether a good correlation exists
between bioluminescent signal ((Bioluminescencetreated C Biolu-
minescence signaluntreated) 100) and cell survival in treated
SKOV3
Luc cells. Experiments were performed in triplicate.
Bioluminescent imaging
Bioluminescent imaging was performed with the IVISt Imaging
System, composed of a high sensitivity cooled charge-coupled
camera mounted in a light-tight box (Xenogen, Alameda, CA,
USA). The commercially available Living Imaget software
(Xenogen, Alameda, CA, USA) was used to collect and analyse
images. For in vitro imaging, the bioluminescent signal was
obtained over a 60-s integration period. For in vivo imaging, mice
were pre-anaesthetised (Ketamine/Xylazine, 100, 10mgkg
 1 res-
pectively) and were administered D-luciferin potassium salt in
saline (100mgkg
 1) intraperitoneally. Animals were then placed in
an air-tight box in the imaging chamber (with heated stage, 371C)
at a distance allowing for whole body imaging in a single field of
view. Gray-scale images were initially obtained to provide an
anatomical reference for the bioluminescent images, which were
then acquired over a 5-min integration time. Regions of interest
covering the entire peritoneal cavity were selected, including
tumours and total photon counts were determined. Bioluminescent
images were collected at various time points throughout the
duration of the study.
Generation of xenografts
Female SCID mice (4- to 6-week-old, 18–20g), obtained from the
University Health Network animal colony (Toronto, ON, Canada)
were injected intraperitoneally with 1 10
7 SKOV3
Luc cells,
suspended in 200ml of RPMI-1640 medium. Animals were housed
under sterile conditions in microisolator cages, fed standard chow
diet with water ad libitum and maintained on an automatic 12-h
light cycle at 22–241C. All studies were conducted using sterile
techniques and in accordance with the guidelines of the University
Health Network Animal Care Committee and the Canadian Animal
Care Council.
Treatment groups
Tumour bearing mice received PTX (60mgkg
 1 total dose over 3
weeks) either as intermittent therapy (i.p. bolus injections of
20mgkg
 1 Taxol
s on a q7d 3 schedule) or sustained therapy
(PTXePC surgically implanted i.p., providing sustained delivery of
20mgkg
 1 per week) and were compared with controls (drug-free
ePC implant). Prior to treatment initiation, release from PTXePC
was confirmed both in vitro and in vivo as described earlier (Grant
et al, 2005; Ho et al, 2005; Vassileva et al, 2007). Treatment was
initiated 7 days post SKOV3
Luc inoculation, referred to as Day 0;
on this date, three mice were killed for visual and microscopic
tumour inspection/analysis, and the remainder of the animals
(n¼36), were separated into the various groups as described
above (n¼12/each group). Mice were imaged every 2 days post
SKOV3
Luc tumour inoculation, at treatment initiation, 24-h post-
treatment initiation and every 2–3 days throughout the course of
treatment until the termination of the study. Each week (Days 7, 14
and 21), three mice from each group were randomly selected and
killed for analysis of tumours and tissues. Owing to rapid disease
progression, a maximum 4-week monitoring period was estab-
lished. Animals were monitored daily for normal activity,
abdominal swelling (peritonitis), weight loss, muscle wasting,
abdominal distension, and under-conditioning to assess treat-
ment-related toxicities and disease progression. To monitor
abdominal distension, we utilised an autoclavable, fabric measur-
ing tape to measure abdominal girth two times weekly, commen-
cing at the day of tumour inoculation. To assess under-
conditioning and muscle wasting, we used the ‘body conditioning
scoring’ system as described earlier (Ullman-Cullere ´ and Foltz,
1999). Briefly, this was done by monitoring changes in flesh
coverage of bony protuberances. This has been shown to
accurately reflect the health decline in mice that have organ
enlargement, such as tumour burden growth. End points included:
(1) inactivity, hypothermia, or hunched posture; (2) muscle
wasting and under-conditioning using body condition scoring;
(3) weight loss or gain in excess of 20%; (4) ulceration/infection at
tumour site; or (5) excessive distension of the abdomen as assessed
by abdominal girth measurements. Animals that reached these
pre-determined ethical end points related to tumour burden and
body conditionings were killed. Kaplan–Meier survival curves
were constructed.
Plasma, tumour and liver drug concentrations were measured by
high performance liquid chromatography as described earlier
(Vassileva et al, 2007). As intraperitoneal ovarian xenografts
disseminate throughout the peritoneal cavity, all macroscopic
(visible) tumour nodules were excised, harvested and weighed,
followed by fixation in 4% paraformaldehyde (PFA) solution.
Tumour tissues were paraffin embedded, processed and sectioned.
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sMarkers of proliferation (Ki-67) and apoptosis (terminal deoxy-
transferase-mediated dUTP nick-end labeling and Caspase 3) were
examined.
Immunohistochemistry
Paraffin sections were dewaxed in xylene, passaged through graded
alcohols and rinsed in distilled water. Sections were immersed in
10mM citrate buffer, pH 6, at 95–1001C for 20min in a
microwavable pressure cooker; cooled and rinsed in PBS, then
treated with 1% Pepsin (Sigma, Oakville, ON, Canada) in 0.01 N
HCl (pH 2.0) for 15min at 371C. Endogenous peroxidase and
biotin activity were blocked using 3% hydrogen peroxide and
avidin/biotin blocking kit (Lab Vision, Fremont, CA, USA). For the
assessment of proliferation, sections were incubated at room
temperature with the Ki-67 monoclonal antibody (Invitrogen,
Burlington, ON, Canada), 1/50 dilution for 1h. For the assessment
of apoptosis, sections were incubated with active caspase 3 (casp3)
antibody (Chemicon, Temecula, CA, USA), 1/50 dilution overnight,
or with biotin-nucleotide cocktail and DNA polymerase 1
(Promega, Madison WI, USA) for 1h at 371C for in situ terminal
deoxytransferase-mediated dUTP nick-end labeling (TUNEL).
Colour development was done with freshly prepared NovaRed
solution (Vector Laboratories, Burlington, ON, Canada). Sections
were counterstained lightly with Mayer’s haematoxylin, dehy-
drated in alcohols, cleared in xylene and mounted in Permount
(Fischer, Ottawa, ON, Canada). Nuclei that stained brownish-red
were scored as positive and those that stained blue were scored as
negative.
Quantification of tumour proliferation and apoptosis
Tumour sections were imaged using a Nikon Coolpix 990 colour
camera mounted on a Nikon Eclipse e400 microscope (Japan). At
least 10 fields ( 400) were randomly selected from each slide.
Positively and negatively stained nuclear areas were collected by
using Image J analysis software (NIH, Bethesda, MD, USA). Ki-67,
Casp3 and TUNEL-labeling indices were determined as the ratio of
areas occupied by the positively stained tumour cell nuclei relative
to all tumour cell nuclei.
Statistical analysis
Data are expressed as means±s.e. Data were analysed using one-
way ANOVA and the paired Student’s t-test of unequal variance for
comparison between groups. Regression analysis was performed to
establish correlations and the log-rank test for survival analysis.
Differences were considered statistically significant at Po0.05.
RESULTS
In vitro evaluation of PTX in SKOV3
Luc cells
PTX inhibited SKOV3
Luc cell survival in a concentration and time-
dependent manner as evaluated by BLI and MTT. As duration of
exposure was increased, cell survival decreased and the IC50 values
were 683±72, 137±29 and 27±12nM PTX at 24, 48 and 72h,
respectively. The bioluminescent signal (% control) significantly
correlated with the MTT assessment of cell viability (Figure 1).
Furthermore, SKOV3
Luc sensitivity to PTX was similar to the
parental SKOV3 cell line (data not shown).
In vivo evaluation of sustained and intermittent PTX
chemotherapy
The effect of sustained vs intermittent intraperitoneal PTX
administration was examined in vivo in the SKOV3
Luc xenograft
model of human ovarian cancer in SCID mice. Sustained
intraperitoneal PTX delivery with PTXePC resulted in significant
reduction of tumour growth, whereas intermittent therapy with
Taxol had no significant effect on tumour reduction as measured
by bioluminescent imaging and tumour weight (Figure 2A–C).
Bioluminescence counts strongly correlated with tumour weight
(Figure 2D). The difference in tumour growth between treatment
groups was also reflected by Ki-67 proliferation indices. Sus-
tained PTX administration with PTXePC significantly reduced the
proliferation index of tumours as compared with both control- and
Taxol-treated mice. Moreover, intermittent therapy with Taxol
resulted in a significant gradual increase in tumour proliferation as
compared with control- and PTXePC-treated animals (Figures 3A
and 4). Proliferation indices significantly correlated with tumour
weight (r¼0.98, Po0.05) and bioluminescence signal (r¼0.99,
Po0.05).
To further characterise tumour response to treatment, we
investigated the degree of apoptosis as measured by Caspase 3 and
TUNEL. Sustained PTXePC treatment significantly increased the
proportion of apoptotic tumour cells, whereas intermittent Taxol
therapy had no effect (Figures 3B and C and 4). Moreover,
significant decreases in body weight of control- and Taxol-treated
animals was observed by day 25 post SKOV3
Luc inoculation,
whereas sustained therapy had no deleterious effects (Figure 5),
suggesting that PTXePC chemotherapy was more effective and
better tolerated.
Effects of PTX chemotherapy on survival
Sustained PTX administration with PTXePC significantly increased
the probability of survival, whereas intermittent Taxol treatment
had no significant effects on survival probability (Figure 6). The
median survival times (post-tumour inoculation) for the control
and intermittent (Taxol) group were 21 and 25 days, respectively.
In the PTXePC group, the probability of survival was 89%, however,
all animals were killed on day 26, therefore long-term survival
rates, could not be determined.
PTX concentration levels
PTX concentration levels were measured in plasma, liver, tumour
and ascites each week. In the PTXePC group, sustained PTX plasma
concentrations were seen from days 7 to 21 of treatment. Paclitaxel
concentration levels from the PTXePC-treated group are displayed
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Figure 1 Correlation between bioluminescence and the MTT cell
viability assay in SKOV3
Luc cells in response to various PTX concentrations
and exposure times. There was a significant correlation between both
assays (r¼0.93, Po0.05). Experiments were conducted in triplicates. Data
presented as mean±s.e.
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sin Table 1. As samples were collected 1 week following the final
dose of Taxol, it was not surprising that PTX levels were below
detection limits in all plasma and tissue samples of the intermittent
treatment group.
DISCUSSION
Although intraperitoneal tumour models may offer close repre-
sentation of clinical disease progression, the assessment of
therapeutic efficacy has proven to be a difficult and daunting task
because of animal-to-animal variability. In this context, we created
a stably luciferase-expressing ovarian cancer cell line and
developed an intraperitoneal xenograft model that closely mimics
metastatic ovarian cancer. We observed strong correlations
between the bioluminescent signal with tumour weight and cell
viability and thus employed bioluminescent imaging as a tool to
investigate the effects of sustained vs intermittent intraperitoneal
administration of PTX on ovarian tumour responsiveness. There
are a number of BLI studies monitoring tumour response to
different treatments (Contag et al, 1997; Jenkins et al, 2003a;
McCaffrey et al, 2003; Hollingshead et al, 2004; Peter et al, 2007);
however, our report is the first to explore the potential of sustained
intraperitoneal chemotherapy with real-time progressive observa-
tion in a human ovarian cancer model.
Similarly to previous studies with other cell lines (Jenkins
et al, 2003a,b; Hollingshead et al, 2004), SKOV3
Luc cell survival
strongly correlated with bioluminescence. For instance,
when SKOV3
Luc cells were exposed to PTX for 24, 48 or 72h,
bioluminescence decreased with increasing concentration, which
strongly correlated with the decrease in cell survival. Furthermore,
we demonstrate that SKOV3
Luc cells grew rapidly in vivo and
generated tumours that were detectable by BLI as early as 4 days
post inoculation, which is otherwise impossible with traditional
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Figure 2 Tumour growth of SKOV3
Luc xenografts in response to intraperitoneal chemotherapy. Paclitaxel therapy (60mgkg
 1 total over 3 weeks) was
initiated 7 days post SKOV3
Luc inoculation. Intermittent therapy consisted of 20mgkg
 1 on q7d 3 schedule (days 7, 14, 21) and sustained therapy
consisted of surgical implantation of PTXePC releasing 20mgkg
 1 per week (n¼9 per group). Non-treated and drug-free ePC implant controls were
combined (n¼18). (A) Relative bioluminescence – bioluminescent signal (counts/s) was normalised to treatment initiation date for individual animals (day 7
post SKOV3
Luc inoculation); the number of mice per group changed as the study proceeded, therefore the bioluminescent signal was obtained from n¼39
on day 0 and 7; n¼6–15 per group on day 14; n¼3–8 per group on day 21 and n¼4–5 per group on day 26; (B) Tumour growth curve; n¼3–6
tumours per group at each time point (obtained from n¼3–6 mice per group); (C) Representative examples of successive in vivo bioluminescent images of
tumour growth in the same animal for each group. Each image was collected for 5min. The colour scale bar indicates photon count per pixel. There was a
significant difference in tumour growth between groups as measured by bioluminescence and tumour weight, Po0.05, ANOVA (*). (D) Regression analysis
revealed significant correlation between bioluminescence and tumour weight (r¼0.97, Po0.05). The anatomical location of tumours upon macroscopic
examination reflected bioluminescence.
Efficacy of sustained intraperitoneal chemotherapy
V Vassileva et al
2040
British Journal of Cancer (2008) 99(12), 2037–2043 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sdetection methods. Our tumour model provided sensitive and
non-invasive monitoring of intraperitoneal disease and allowed us
to initiate treatment when tumours reached similar sizes in all
animals. This way, animals with similar-sized tumours were
randomised into the various treatment groups and were monitored
throughout the course of therapy. The luciferase activity in
tumours showed excellent correlation to tumour weight and
proliferation, thus validating the model with more traditional
tumour evaluation methods. Furthermore, the anatomical location
of tumours corresponded to the image obtained by BLI. Similarly,
studies with other tumour models have also reported correlations
between bioluminescence and tumour weight and/or volume
(Peter et al, 2007; Wang et al, 2007), hence supporting the
technique as a sensitive and reliable method of efficacy evaluation.
Although BLI has emerged as a powerful tool for the monitoring
of in vivo disease progression and regression, its use in endo-
genous tumours is limited as it relies on the expression of a
foreign gene and therefore cannot be directly translated into
the clinic (Hollingshead et al, 2004). Furthermore, it is restricted
to small research animals or to the superficial tissues of larger
animals as signal intensity may be attenuated by scattering
(Jenkins et al, 2003a). Bioluminescent imaging is two-dimensional
and unable to obtain in-depth information; however, the develop-
ment of bioluminescent tomography has overcome these
limitations and three-dimensional images are readily generated
(Kumar et al, 2007; Zhang et al, 2008). Bioluminescent imaging
can therefore provide an important window into the effect
of therapy.
Sustained PTX chemotherapy provided by the PTXePC implant
significantly reduced tumour growth and enhanced therapeutic
response and survival rates in comparison to intermittent
Taxol administration at equivalent doses. For instance, tumour
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Figure 3 Effect of intermittent Taxol and sustained PTXePC therapy on
tumour proliferation and apoptosis in SKOV3
Luc xenografts. (A) Ki-67, (B)
Caspase 3 and (C) TUNEL indices. There was a significant difference in
tumour proliferation and apoptosis between all groups at each time point,
Po0.05, ANOVA (*); n¼3–6 tumours per group, with at least 10 fields
per tumour randomly selected from each slide. Data presented as
mean±s.e.
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Figure 4 Representative tumour sections displaying the effect of
intermittent Taxol and sustained PTXePC therapy on tumour proliferation
and apoptosis in SKOV3
Luc xenografts. Paraffin sections, 5mm and  400
magnification. Nuclei stained red/brown were scored as positive and nuclei
that stained blue were scored as negative. Sections obtained on day 14
post-treatment initiation.
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Figure 5 Body weight changes in response to chemotherapy. Control-
and Taxol-treated animals encountered significant weight loss by day 25,
indicating disease progression. Furthermore, weights in the PTXePC
treatment group significantly differed from control- and Taxol-treated
animals, Po0.05, Student’s t-test (*). The number of mice per group
changed as the study proceeded, therefore body weights were obtained
from n¼39 on day 0 and 7; n¼6–15 per group on day 14; n¼3–8 per
group on day 21 and n¼4–5 per group on day 26. Data presented as
mean±s.e.
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sbioluminescence gradually increased by B27 and 11-fold in
the tumours of the control- and Taxol-treated mice, respectively,
with regard to treatment initiation date. Meanwhile, biolumines-
cence in the PTXePC-treated mice did not intensify, indicating
that sustained therapy was more effective. Furthermore, PTXePC
treatment decreased tumour mass and proliferation by B96%
and B63-fold, respectively, as compared with controls, whereas
intermittent therapy resulted in increased tumour growth. Tumour
weights and proliferation indices were B29 and B152-fold
greater, respectively, in the Taxol group in comparison to
PTXePC. Interestingly, intermittent Taxol administration resulted
in a significant gradual increase in proliferative indices in
comparison to non-treated controls, suggesting possible
tumour repopulation in between treatment cycles. Indeed, it is
thought that intermittent chemotherapy may result in increased
rates of tumour repopulation during treatment-free intervals, and
thus limit efficacy (Kim and Tannock, 2005). In this context, there
is extensive evidence supporting the occurrence of increased
tumour repopulation rates during courses of fractionated radio-
therapy; implementation of continuous low-dose radiation sche-
dules have resulted in substantial improvements in local tumour
control and survival times (Malaise and Tubiana, 1966; Szcze-
panski and Trott, 1975; Jung et al, 1990). Similarly, we have
recently demonstrated that sustained Taxol chemotherapy resulted
in decreased tumour proliferation and diminished tumour
repopulation, as compared with intermittent therapy (Edinger
et al, 2003).
In addition to diminished tumour repopulation, this
enhanced tumour responsiveness with PTXePC, may be as a result
of both regional and continuous drug exposure. As ovarian
tumours are predominantly confined to the peritoneal cavity,
intraperitoneal administration allows for high PTX concentrations
directly at the tumour site, whereas continuous exposure increases
the proportion of apoptotic tumour cells (Dedrick et al, 1978;
Rowinsky and Donehower, 1995). Indeed, in the PTXePC treatment
group, PTX concentrations in ascites and tumours were 42 and
4110-fold greater than in plasma, respectively, and were
accompanied by extensive tumour apoptosis. For instance, the
degree of apoptosis in tumours obtained from the PTXePC
treatment group was 416 and 12-fold greater than Taxol and
control groups, respectively, indicating that sustained therapy
was more effective. Improved and more consistent tumour drug
penetration have been previously demonstrated with increased
exposure time to PTX, both in xenografts and in patient tumours
(Kuh et al, 1999). Additional targeting of vascularised tumours
likely occurred through the circulation as clinically relevant and
tolerable drug plasma levels were achieved in the PTXePC-treated
group (range of 12–31ngml
 1 in all animals). However, much
greater concentrations were accomplished in the peritoneal
cavity at the tumour site. Therefore, PTXePC therapy achieved
augmented tumour targeting and diminished systemic toxicity.
Alternatively, peak plasma and liver concentration levels have been
reported to be about 17mgml
 1 and 60mgg
 1 respectively, follow-
ing a single i.p. bolus doses of PTX (20mgkg
 1); concen-
trations associated with numerous toxicities (Tamura et al, 1995;
Glantz et al, 1996; Maier-Lenz et al, 1997; Kuzuya et al, 2001;
Bardelmeijer et al, 2003). The diminished toxicity and enhanced
efficacy with PTXePC was also reflected by the lack of signi-
ficant changes in body weight. Indeed, we have previously
demonstrated favourable toxicity profiles with PTXePC and
augmented toxicity with Taxol (Vassileva et al, 2007). Similarly,
weight loss may be reflective of efficacy, as physical wasting
is an attribute of disease progression with this model. Both
control- and Taxol-treated animals encountered significant
weight loss by day 25, indicating disease progression and limited
efficacy in the case of intermittent Taxol therapy. Therefore,
intermittent therapy results in high systemic levels, which are
associated with dose-limiting toxicity and a short-lived therapeutic
window.
Localised chemotherapy alleviates systemic toxicities and
has demonstrated survival advantages in advanced ovarian
cancer patients; however, catheter-related complications currently
remain a limitation in the clinical application of intraperitoneal
chemotherapy. Our drug delivery system may be a solution to the
problems encountered with current intraperitoneal chemotherapy
administration practices and allow further exploration of localised
drug delivery. Moreover, our formulation provides sustained-
release of PTX, which may further improve efficacy by diminishing
the rates of tumour repopulation and by enhancing tumour cell
apoptosis. We also demonstrate that bioluminescent imaging
enables earlier detection of tumours than traditional methods and
that signal intensity correlates with tumour growth. Therefore,
bioluminescent imaging is a non-invasive and rapid approach for
the monitoring of experimental tumours and should be further
utilised in the pre-clinical evaluation of therapeutic interventions
for ovarian cancer.
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Table 1 Paclitaxel concentrations detected in PTXePC-treated animals
Time
a
Plasma
(ngml
 1)
Tumour
(ngg
 1)
Ascites
(ngml
 1)
Liver
(ngg
 1)
71 7 ±2 337±72 8 ±2 345±155
14 22±4 2443±139 52±7 691±400
21 24±7 1102±609 56±5 558±310
aDays post treatment initiation. Sustained PTX concentrations were observed in the
PTXePC group from days 7 to 21 of treatment. No significant differences in
concentration levels were found. Concentrations based on n¼3 per time point.
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Figure 6 The effects of intermittent Taxol and sustained PTXePC
chemotherapy on survival (Kaplan–Meier curve). Taxol therapy did not
result in significant survival advantages in comparison to controls (P¼0.17),
whereas sustained PTXePC therapy resulted in significant survival
advantages in comparison to control (P¼0.0001) and Taxol-treated
(P¼0.0002) animals.
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